→ Guilford, CT-based LAM Therapeutics raised a $58 million C round for its work on new drugs for cancer and rare diseases. “This week’s Bert Vogelstein paper in Science showed us that next-generation sequencing and math can help us to understand cancer,” said Jonathan Rothberg, a LAM co-founder and the recipient of the National Medal of Technology for inventing next-generation sequencing. “Sequencing coupled with deep learning is going to enable us to cure cancer.”
→ Make no mistake about it. Regeneron chief scientist and co-founder George Yancopoulos thinks it would be nuts to cut NIH funding. “Do you pray for an iPhone?” Yancopoulos said, according to a report in Bloomberg. “God forbid, I’ve had situations with my parents, my loved ones, my children, when they have a serious disease, that’s when we pray, and that’s why as a society, we have to make some decisions about what to invest in.”
→ Foundation Medicine will put its genomics platform to work for Bristol-Myers Squibb, identifying predictive biomarkers such as Tumor Mutational Burden and Microsatellite Instability in patients enrolled across clinical trials investigating the biopharma company’s cancer immunotherapies.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription